A compound genetic/genomic and microenvironmental risk classification for localized prostate cancer

As we become more knowledgeable about the underlying genetic and other factors that affect the risk for, and the risk for progression of, apparently localized prostate cancer, we also become more able to predict such risks … but this is a very complex topic. … READ MORE …

“Diet, nutrition, physical activity and prostate cancer”

A new report issued here in the USA by the American Institute for Cancer Research (AIRC) and globally by the World Cancer Research Fund International is focused on “Diet, Nutrition, Physical Activity and Prostate Cancer“. … READ MORE …

Focal therapy today: upsides and downsides

While there is considerable allure to the theory behind focal therapy (and focal laser therapy or FLA in particular) as a treatment for some men with localized prostate cancer, it is worth understanding that there are good reasons to consider this allure with great caution. … READ MORE …

HHV8 infection NOT associated with risk for prostate cancer

Over the years there have been many suggestions that prostate cancer may be “caused” by one or more viral or bacterial infections. … READ MORE …

Factors in the sequencing of late-stage prostate cancer treatments

A paper in the International Journal of Cancer offers information on the sequencing of cabazitaxel (CAB) and abiraterone acetate (ABI) in men with metastatic, castration-resistant prostate cancer (mCRPC) who have already progressed after treatment with docetaxel. … READ MORE …

New US national prostate cancer data classified by NCCN risk category

Prior to 2013, when the National Cancer Institute released accumulated, de-identified, prostate cancer-specific patient data from the national SEER cancer registry, those data only included the post-surgical, pathological Gleason scores and not the biopsy Gleason scores. … READ MORE …

Poorer outcomes for BRCA1/2 carriers after standard treatment

It is not entirely surprising to come across a paper suggesting that male carriers of the BRCA1/2 genes are at risk for worse post-treatment outcomes than non-carriers of these genes after standard forms of first-line treatment for prostate cancer. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,175 other followers